Navigation Links
Dr. Tom Maniatis honored with 2012 Lasker-Koshland Special Achievement Award in Medical Science
Date:9/10/2012

NEW YORK (September 10, 2012) ― Tom Maniatis, PhD, the Isidore S. Edelman Professor of Biochemistry and chair of the Department of Biochemistry and Molecular Biophysics at Columbia University Medical Center, is to receive the 2012 Lasker-Koshland Special Achievement Award in Medical Science. Dr. Maniatis is known for both his research on the mechanisms of gene regulation and his Molecular Cloning Manual. Dr. Maniatis will receive the award on Sept. 21 in New York City.

"I am deeply honored to receive the Lasker Special Achievement Award in Medical Science," said Dr. Maniatis. "I became a scientist because of the excitement of making discoveries, but to see the impact of these discoveries on the treatment of human disease has been particularly gratifying."

"Tom Maniatis' work is the quintessential example of the path from basic science to clinical applications," said Lee Goldman, MD, executive vice president of Columbia University and dean of the faculties of health sciences and medicine at Columbia University Medical Center. "His cloning manual is used by researchers worldwide, while his research contributions are at the foundation of current thinking about genetics."

In 1980 James Watson, PhD, director of Cold Spring Harbor Laboratory (CSHL), asked Maniatiswho was on the Harvard faculty at the timeto teach new genetic engineering techniques during a summer course at CSHL and then to produce a manual. The resultant Molecular Cloning Manualpublished in 1982 and often referred to as "the Bible" by students and researcherscontained practically every technique biologists needed to manipulate DNA.

Scientists could now identify genes that cause disease and then produce new drugs such as human insulin; and the techniques were indispensable for the success of the Human Genome Project. Dr. Maniatis' laboratory developed many of the techniques in the manual, which he coauthored with his postdoctoral fellow Ed Fritsch, PhD, and Joe Sambrook, PhD, the scientific director at CSHL.

Using the new techniques, Dr. Maniatis was the first to isolate a human gene and to use the cloned gene to identify deletion and substitution mutations that cause disease. The gene beta globin, for example, is part of the hemoglobin complex, and the mutations Dr. Maniatis identified cause a blood disease called beta thalassemia.

Maniatis also created the first complete human "genomic" DNA librarya collection of DNA containing every human genewhich made it possible to isolate and study any human gene. As with his genetic engineering techniques, Maniatis freely shared this library with other researchers.

In other research, Dr. Maniatis and his students uncovered important details of how information in genes is turned into proteins, including the mechanisms of transcription and RNA splicing.

Not content to see discoveries remain in the basic science community, Dr. Maniatis also helped launch the biopharmaceutical industry. In 1980, he cofounded Genetics Institute (eventually bought by Wyeth), which developed blood clotting factors, erythropoietin (EPO), and bone morphogenic (BMP) proteins. ProScript, which Dr. Maniatis cofounded in 1994, developed a cancer drug from discoveries made in his lab. That drug, Velcade (bortezomib), is now the most effective treatment for multiple myeloma, as well as the forerunner of a class of anti-cancer drugs that target a cellular protease called the proteasome.

From the days of sharing the techniques of recombinant DNA with the world, to improving human health through biotech ventures, "Tom has always had a deep sense that science must be shared," said Richard Axel, MD, University Professor, and a good friend of Maniatis.

Dr. Maniatis moved to Columbia University Medical Center in 2010. One reason for relocating was the transforming impact of his sister's death from Amyotrophic lateral sclerosis (ALS). Initially, Dr. Maniatis was a consultant for the ALS Association, but he later jumped into ALS research himself, devoting half his lab's time to the search for the causes of the disease.

"The Motor Neuron Center at Columbia was a huge attraction," said Maniatis. "I was going in the direction of molecular neuroscience, and there is no better place in the world to do that than Columbia."

Extending his influence beyond CUMC, Dr. Maniatis helped co-found the New York Genome Center, which combines the resources of 11 scientific institutions, including Columbia and New York-Presbyterian. Once it is up and running at full capacity in 2013, the center will be one of the largest sequencing and analysis facilities in the country.

Biography

Tom Maniatis received his BA and MS from the University of Colorado at Boulder and his PhD in molecular biology from Vanderbilt University. He did postdoctoral studies at Harvard and at the Medical Research Council Laboratory of Molecular biology in Cambridge, England. He has also held a research position at Cold Spring Harbor Laboratory and was on the faculty of California Institute of Technology. He spent 30 years at Harvard University, where he became chair of the Department of Molecular and Cellular Biology in 1985. In 2010, Dr. Maniatis moved to Columbia University Medical Center.

Dr. Maniatis has been elected to some of the most prestigious organizations in the scientific world: the U.S. National Academy of Sciences, the American Academy of Arts and Sciences, the American Academy of Microbiology, and the American Association for the Advancement of Science.

He has also been honored with the Donald Mulder Award for ALS research from the ALS Association, honorary PhDs from the Watson School of Biological Sciences at Cold Spring Harbor Laboratory and the University of Athens in Greece, a Scientific Achievement Award from the American Medical Association, the Eli Lilly Research Award in Microbiology and Immunology from the American Society of Microbiology, the Novartis Drew Award in Biomedical Research, and the Richard Lounsbery Award for Biology and Medicine from the U.S. and French national academies of science.


'/>"/>
Contact: Karin Eskenazi
ket2116@columbia.edu
212-342-0508
Columbia University Medical Center
Source:Eurekalert  

Related biology news :

1. Science research led in Gulf of Mexico by Penn State biologist to be honored with US award
2. Jeff Crandall Honored With SAE International Arnold W. Siegel International Transportation Safety Award
3. Inventor honored for bridging innovation and humanitarianism to help millions globally
4. 2012 ARVO Award recipients honored at annual meeting
5. Researcher who identifed genetic cause and possible treatment for Marfan syndrome honored
6. Carnegies Donald Brown wins Lasker-Koshland Award
7. The ENCODE Project publishes new genomic insights in special issue of Genome Research
8. Dawn of humanity illuminated in special journal edition 50 years after the Leakeys
9. Dawn of humanity illuminated in special journal edition - 50 years after the Leakeys
10. Lower vitamin D could increase risk of dying, especially for frail, older adults
11. Professors essay is 1 of 10 in special issue of Daedalus
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Dr. Tom Maniatis honored with 2012 Lasker-Koshland Special Achievement Award in Medical Science
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/21/2016)... , March 22, 2016 ... recognition with passcodes for superior security   ... a leading provider of secure digital communications services, today ... biometric technology and offer enterprise customers, particularly those in ... facial recognition and voice authentication within a mobile app, ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... -- Regular discussions on a range of subjects including policies, debt ... said Poloz. Speaking at a lecture to the ... pointed to the country,s inflation target, which is set by ... "In certain areas there needs to ... goals, why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology: